<DOC>
	<DOCNO>NCT00234572</DOCNO>
	<brief_summary>The purpose study compare effectiveness lanreotide autogel placebo single injection . Effectiveness safety also assess follow four fixed-dose injection one year treatment give titrated dos .</brief_summary>
	<brief_title>Efficacy Safety Study Varying Doses Lanreotide Autogel Patients With Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>documentation diagnosis active acromegaly base either follow definition : 1. patient never receive somatostatin analog dopaminergic agonist previously receive medication stop 3 month visit 1 mean growth hormone ( GH ) level &gt; 5ng/mL visit 1 ; 2. patient receive treatment somatostatin analog ( lanreotide autogel ) dopaminergic agonist visit 1 , mean GH &gt; 3ng/mL visit 2 ( visit 2a ) least 100 % increase mean GH level visit 1 visit 2 ( visit 2a ) receipt radiotherapy acromegaly within 3 year pituitary surgery within 3 month prior visit 1 prior receipt lanreotide autogel GH antagonist anticipate need pituitary surgery ( adenomectomy ) radiotherapy study period know hypersensitivity test material relate compound clinically significant renal hepatic abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>